Literature DB >> 21187460

MCF-7 cell apoptosis and cell cycle arrest: non-genomic effects of progesterone and mifepristone (RU-486).

Renathe Fjelldal1, Bjørn T Moe, Anne Ørbo, Georg Sager.   

Abstract

UNLABELLED: The pharmacology of progestins includes actions initiated by various cellular targets, including classic receptors characterized as nuclear transcription factors (nPR), G-protein-coupled membrane receptors (mPR), enzymes, membrane channels and transporters. The effects initiated by targets other than nPR are termed non-genomic and there is an increasing recognition that these effects also play an important role in the regulation of cell growth.
MATERIALS AND METHODS: The nPR-positive breast cancer (MCF-7) and the nPR-negative uterine cervix cancer (C4-I) cell lines were exposed to progesterone (PG) and mifepristone (MF) during a culture period of 96 h. Daily cell count, cell cycle analysis and apoptosis assay were performed.
RESULTS: It was possible to separate the nPR initiated effects (growth stimulation) from the non-genomic effects (growth inhibition) in the MCF-7 cells. Below 1 μM PG treatment gave a small, but distinct increase in cell density which was effectively blocked by MF. Such an effect was absent from the nPR-negative C4-I cells. For a range of concentrations between 1 μM and 100 μM, the effect of both PG and MF developed over time and showed concentration dependency. The PG concentrations needed to reduce cell density by 50% (IC(50)) were 12.8 ± 1.1 μM and 6.5 ± 0.2 μM for the MCF-7 and C4-I cells, respectively. MF appeared to be equally or slightly more potent, with respective IC(50) values of 6.9 ± 0.5 μM and 5.3 ± 0.3 μM. The cell density reduction was both a result of cell cycle arrest and apoptosis. The combination of PG and MF had a potentiated effect on cell density reduction, cell cycle arrest and apoptosis.
CONCLUSION: The antiproliferative/cytotoxic effect of PG and MF in concentrations between 1 and 100 μM is of a non-genomic nature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187460

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Progesterone inhibits the growth of human neuroblastoma: in vitro and in vivo evidence.

Authors:  Fahim Atif; Iqbal Sayeed; Seema Yousuf; Tauheed Ishrat; Fang Hua; Jun Wang; Daniel J Brat; Donald G Stein
Journal:  Mol Med       Date:  2011-06-17       Impact factor: 6.354

2.  A polygenic-score-based approach for identification of gene-drug interactions stratifying breast cancer risk.

Authors:  Andrew R Marderstein; Scott Kulm; Cheng Peng; Rulla Tamimi; Andrew G Clark; Olivier Elemento
Journal:  Am J Hum Genet       Date:  2021-08-06       Impact factor: 11.025

3.  Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.

Authors:  Chelsea R Tieszen; Alicia A Goyeneche; BreeAnn N Brandhagen; Casey T Ortbahn; Carlos M Telleria
Journal:  BMC Cancer       Date:  2011-05-27       Impact factor: 4.430

Review 4.  The Role of Mifepristone in Meningiomas Management: A Systematic Review of the Literature.

Authors:  Giulia Cossu; Marc Levivier; Roy Thomas Daniel; Mahmoud Messerer
Journal:  Biomed Res Int       Date:  2015-06-03       Impact factor: 3.411

5.  Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo study.

Authors:  Mariana Segovia-Mendoza; Rafael Jurado; Roser Mir; Luis A Medina; Heriberto Prado-Garcia; Patricia Garcia-Lopez
Journal:  BMC Cancer       Date:  2015-01-27       Impact factor: 4.430

Review 6.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

7.  CCM signaling complex (CSC) couples both classic and non-classic Progesterone receptor signaling.

Authors:  Johnathan Abou-Fadel; Xiaoting Jiang; Brian Grajeda; Akhil Padarti; Cameron C Ellis; Esmeralda Flores; Alyssa-Marie D Cailing-De La O; Jun Zhang
Journal:  Cell Commun Signal       Date:  2022-08-15       Impact factor: 7.525

8.  CmPn signaling networks in the tumorigenesis of breast cancer.

Authors:  Mellisa Renteria; Ofek Belkin; David Jang; Justin Aickareth; Muaz Bhalli; Jun Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

9.  Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells.

Authors:  Stacy L Wempe; Carlos D Gamarra-Luques; Carlos M Telleria
Journal:  Cancer Growth Metastasis       Date:  2012-01-28

10.  Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression.

Authors:  Rong Liu; Peiguo Shi; Zhi Nie; Huichun Liang; Zhongmei Zhou; Wenlin Chen; Haijun Chen; Chao Dong; Runxiang Yang; Suling Liu; Ceshi Chen
Journal:  Theranostics       Date:  2016-02-13       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.